Publication

Duca FA, Côté CD, Rasmussen BA, Zadeh-Tahmasebi M, Rutter GA, Filippi BM, Lam TKT. 2015. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 21:506–11. doi:10.1038/nm.3787.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 372:2006–17. doi:10.1056/NEJMoa1414428.

Long M, Tao S, de la Vega MR, Jiang T, Wen Q, Park SL, Zhang DD, Wondrak GT. 2015. Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. Cancer Prev Res (Phila). 8:444–54. doi:10.1158/1940-6207.CAPR-14-0359.

Côté CD, Rasmussen BA, Duca FA, Zadeh-Tahmasebi M, Baur JA, Daljeet M, Breen DM, Filippi BM, Lam TKT. 2015. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med. 21:498–505. doi:10.1038/nm.3821.

Song L-N, Silva J, Koller A, Rosenthal A, Chen EI, Gelmann EP. 2015. The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase. Mol Cancer Res. 13:913–22. doi:10.1158/1541-7786.MCR-14-0680.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, et al. 2015. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med. 7:438–49. doi:10.15252/emmm.201404580.

Scott AJ, Messersmith WA, Jimeno A. 2015. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 51:223–9. doi:10.1358/dot.2015.51.4.2320599.

Aldrich JC, Maggert KA. 2015. Transgenerational inheritance of diet-induced genome rearrangements in Drosophila. PLoS Genet. 11:e1005148. doi:10.1371/journal.pgen.1005148.

Lightner AL, Shurell E, Dawson N, Omidvar Y, Foster N. 2015. A single-center experience and review of the literature: 64 cases of phyllodes tumors to better understand risk factors and disease management. Am Surg. 81:309–15.

Moore IMK, Gundy P, Pasvogel A, Montgomery DW, Taylor OA, Koerner KM, McCarthy K, Hockenberry MJ. 2015. Increase in oxidative stress as measured by cerebrospinal fluid lipid peroxidation during treatment for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 37:e86–93. doi:10.1097/MPH.0000000000000258.

Klebba JE, Buster DW, McLamarrah TA, Rusan NM, Rogers GC. 2015. Autoinhibition and relief mechanism for Polo-like kinase 4. Proc Natl Acad Sci U S A. 112:E657–66. doi:10.1073/pnas.1417967112.

Romanoski CE, Glass CK, Stunnenberg HG, Wilson L, Almouzni G. 2015. Epigenomics: Roadmap for regulation. Nature. 518:314–6. doi:10.1038/518314a.

Stocke NA, Meenach SA, Arnold SM, Mansour HM, Hilt JZ. 2015. Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. Int J Pharm. 479:320–8. doi:10.1016/j.ijpharm.2014.12.050.

Elshan NGRD, Jayasundera T, Anglin BL, Weber CS, Lynch RM, Mash EA. 2015. Trigonal scaffolds for multivalent targeting of melanocortin receptors. Org Biomol Chem. 13:1778–91. doi:10.1039/c4ob02094d.

Klebba JE, Galletta BJ, Nye J, Plevock KM, Buster DW, Hollingsworth NA, Slep KC, Rusan NM, Rogers GC. 2015. Two Polo-like kinase 4 binding domains in Asterless perform distinct roles in regulating kinase stability. J Cell Biol. 208:401–14. doi:10.1083/jcb.201410105.

Pozo K, Hillman A, Agustiyn A, Plattner F, Raezani S, Singh T, Sun X, Minna J, Cote G, Chen H, et al. 2015. *equal contributors (2015) Differential expression of cell cycle regulators in Cdk5-dependent neuroendocrine thyroid cancer tumorigenesis. Oncotarget, 6:12080-93.

O’Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, et al. 2015. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 26:1923–9. doi:10.1093/annonc/mdv264.

Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP. 2015. EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. J Frailty Aging. 4:107–10. doi:10.14283/jfa.2015.48.

Thorne CA, Wichaidit C, Coster AD, Posner BA, Wu LF, Altschuler SJ. 2015. GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors. Nat Chem Biol. 11:58–63. doi:10.1038/nchembio.1690.

Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, et al. 2015. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 10:e0126312. doi:10.1371/journal.pone.0126312.

Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, et al. 2015. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 125:236–41. doi:10.1182/blood-2014-06-584623.

Savar A, Acin S, Gonzalez CL, El-Sawy T, Mejia O, Li Z, Esmaeli B, Lacy-Hulbert A, El-Naggar AK, McCarty JH, et al. 2015. Loss of epithelial p53 and αv integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment. Oncogene. 34:516–24. doi:10.1038/onc.2013.585.

Lu J, Liu C, Wang P, et al. "The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin." Biomaterials. 2015;62:176-87. PMCID: PMC4470812 PMID: 26057133. 2015.

Miller JA, Pappan K, Thompson PA, Want EJ, Siskos AP, Keun HC, Wulff J, Hu C, Lang JE, Chow H-HS. 2015. Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention. Cancer Prev Res (Phila). 8:86–93. doi:10.1158/1940-6207.CAPR-14-0100.

Martinez-Ariza G, Hulme C. 2015. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. Pharm Pat Anal. 4:387–402. doi:10.4155/ppa.15.20.